Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its ...

I’d rather just be a surfer…like anyone else. I’d rather be Pete. Maybe I’d like to be “the voice over guy”…but I never ...

Get a sneak peek as to why blind guys can’t cheat and see who is always telling all of their secrets to the entire world by ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...